Syndax Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
35 Gatehouse Dr Fl 3 Bldg D, Waltham, Ma...Phone Number
(781) 419-1400Website
www.syndax.comRevenue
$252.3 MillionStock Symbol
SNDXIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company incorporated in 2005 and headquartered in New York, New York, focused on the discovery, development, and commercialization of therapies for cancer. The company specializes in oncology, with a primary focus on acute leukemias and chronic graft-versus-host disease. Its pipeline includes a menin inhibitor approved for the treatment of relapsed or refractory acute leukemias driven by specific genetic mutations, as well as a monoclonal antibody targeting the CSF-1 receptor for chronic graft-versus-host disease and additional cancer indications. Syndax is advancing its transition to a fully integrated commercial biopharmaceutical organization, with ongoing clinical development programs across hematologic malignancies and other serious conditions. The company trades on the NASDAQ under the ticker symbol SNDX.Explore more
Syndax Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Syndax Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Syndax Pharmaceuticals
Funding: Get notified immidiatlly once Syndax Pharmaceuticals has new funding data
Check if Syndax Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Syndax Pharmaceuticals launches new products
Click to see if Syndax Pharmaceuticals had a recent Job posting/layoffs
Earning: See what the market has to say on Syndax Pharmaceuticals recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Syndax Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Syndax Pharmaceuticals is spiking on competitors!
Recommended Actions
Find VP level buyers at Syndax Pharmaceuticals
Find 3 more new buyers
Compare Similar Companies to Syndax Pharmaceuticals
Compare insights from companies similar to Syndax Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Syndax Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Syndax Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Syndax Pharmaceuticals.
Syndax Pharmaceuticals financials insights
Gather financial insights about Syndax Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Series B
$26.6M
2014
Debt
$4.9M
2015
Series C
$80M
2016
Stock Offering
$50.5M
2017
Stock Offering
$48.7M
Stock Offering
$25M
2019
Stock Offering
$26.2M
2020
Multiple Rounds
$323.8M
Syndax Pharmaceuticals Tech Stack
A closer look at the technologies used by Syndax Pharmaceuticals
Most Recent Scoops
Open Position
Event
will be presenting additional clinical evidence from multiple trials at major medical meetings in H2 of the year, building on its presence at ASCO and EHA in June, with data in relapsed/refractory NUP98-rearranged acute leukemia expected to be published in Q4.
Events, Medical Research, Clinical Operations
Project
Syndax Pharmaceuticals announced that groundbreaking preclinical studies with revumenib were published in July, demonstrating that menin is a novel dependency in proliferative megakaryocytes, major drivers of myelofibrosis, providing the scientific basis for the company's clinical development program in myelofibrosis.
Medical Research, Pharmaceuticals
Earnings
Syndax Pharmaceuticals has reported that patients on therapy post-transplant are averaging at least 9 months of treatment duration, while patients who do not receive a transplant are averaging over 7 months on therapy, with both durations expected to increase over time.
Pharmaceuticals
Project
Medical Research, Clinical Operations
Syndax Pharmaceuticals News & Media
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September 1, 2026, the Company granted inducement awards to purchase up to 175,000 shares of common stock to nineteen new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commSyndax Announces Participation in September Investor Conferences
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on August 1, 2026, the Company granted inducement awards to purchase up to 59,250 shares of common stock to five new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencementSyndax Pharmaceuticals, Inc. (SNDX) Q2 2026 Earnings Call Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Q2 2026 Earnings Call August 4, 2026 4:30 PM EDTCompany ParticipantsSharon Klahre - Vice President of Investor Relations...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Syndax Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company incorporated in 2005 and headquartered in New York, New York, focused on the discovery, development, and commercialization of therapies for cancer. The company specializes in oncology, with a primary focus on acute leukemias and chronic graft-versus-host disease. Its pipel... Read More
